Skip to main content

Press Releases

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Date Title
Toggle Summary Sienna Biopharmaceuticals to Present at JMP Securities Life Science Conference
WESTLAKE VILLAGE, Calif. , June 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the JMP Securities Life Science Conference ,
Toggle Summary Sienna Biopharmaceuticals to Present at Jefferies Healthcare Conference
WESTLAKE VILLAGE, Calif. , May 31, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Jefferies 2018 Global Healthcare Conference,
Toggle Summary Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breaker at the International Investigative Dermatology Congress
WESTLAKE VILLAGE, Calif. , May 16, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that pre-clinical data from the Company’s topical product candidate SNA-125, a novel, selective kinase inhibitor currently in Phase 1/2 proof-of-concept clinical trials for
Toggle Summary Sienna Biopharmaceuticals Reports First Quarter 2018 Financial Results
WESTLAKE VILLAGE, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the first quarter of 2018. “We are pleased to report the results of our first quarter,” said Frederick C.
Toggle Summary Sienna Biopharmaceuticals to Present at BAML Health Care Conference
WESTLAKE VILLAGE, Calif. , May 11, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Bank of America Merrill Lynch Health Care
Toggle Summary Sienna Biopharmaceuticals Appoints Caroline Van Hove as Chief Commercial Officer
-- Expansion of Leadership Team Enables Sienna to Prepare for Commercial Focus with Five Development Programs Now in the Clinic WESTLAKE VILLAGE, Calif. , March 22, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of Caroline Van Hove as the
Toggle Summary Sienna Biopharmaceuticals Appoints John W. Smither as Chief Financial Officer
Richard Peterson Departing for Personal Reasons WESTLAKE VILLAGE, Calif. , March 21, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of John W. Smither as the Company’s Chief Financial Officer. Mr.
Toggle Summary Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
-- Pipeline Includes Five Clinical-Stage Programs -- Data from Five Clinical Programs Expected, Beginning in 2H18 WESTLAKE VILLAGE, Calif. , March 15, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the fourth quarter and
Toggle Summary Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
-- Trial to Enroll Approximately 30 Patients with Atopic Dermatitis -- Top-Line Results Expected in Fourth Quarter of 2018 WESTLAKE VILLAGE, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc.  (NASDAQ:SNNA) today announced that the first patient has been dosed in the
Toggle Summary Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference
WESTLAKE VILLAGE, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Cowen and Company 38 th Annual Health Care
Toggle Summary Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125
-- Trial to Enroll Approximately 15 Patients with Psoriasis -- Top-Line Results Expected in Third Quarter of 2018 WESTLAKE VILLAGE, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed in the Company’s
Toggle Summary Sienna Biopharmaceuticals to Present at J.P. Morgan Healthcare Conference
WESTLAKE VILLAGE, Calif. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III , M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the 36 th Annual J.P.